Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Anticancer bispecific antibody R&D advances: a study focusing on research trend worldwide and in China

Fig. 1

The trend of anticancer bsAbs clinical trials with different clinical stages and status (up to December 2020). a Clinical stages of overall clinical trials. b Clinical stages of international companies. c Clinical stages of China-initiated or involved companies. d Research status and enrollment of overall clinical trials. e Research status and enrollment of international companies. f Research status and enrollment of China-initiated or involved companies. The MOA of bsAbs clinical trials. g MOA of overall clinical trials. h MOA of international companies. i MOA of China-initiated or involved companies. Network graph characterizing the target pairs of bispecific antibodies. Each dot in the figure is a target, and each line connecting two circular nodes represents a bsAbs. The size of the dot is proportional to the number of pairs of the target with other different targets, and the width of the line is proportional to the number of clinical trials of the target. j Target pairs of overall clinical trials. k Target pairs of international companies. l Target pairs of China-initiated or involved companies

Back to article page